Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression
The aim of this study was to investigate predictors of progressive cognitive deterioration in patients with suspected non-Alzheimer disease pathology (SNAP) and mild cognitive impairment (MCI). We measured markers of amyloid pathology (CSF β-amyloid 42) and neurodegeneration (hippocampal volume on MRI and cortical metabolism on [(18)F]-fluorodeoxyglucose-PET) in 201 patients with MCI clinically followed for up to 6 years to detect progressive cognitive deterioration. We categorized patients with MCI as A+/A- and N+/N- based on presence/absence of amyloid pathology and neurodegeneration. SNAPs were A-N+ cases. The proportion of progressors was 11% (8/41), 34% (14/41), 56% (19/34), and 71% (60/85) in A-N-, A+N-, SNAP, and A+N+, respectively; the proportion of APOE ε4 carriers was 29%, 70%, 31%, and 71%, respectively, with the SNAP group featuring a significantly different proportion than both A+N- and A+N+ groups (p ≤ 0.005). Hypometabolism in SNAP patients was comparable to A+N+ patients (p = 0.154), while hippocampal atrophy was more severe in SNAP patients (p = 0.002). Compared with A-N-, SNAP and A+N+ patients had significant risk of progressive cognitive deterioration (hazard ratio = 2.7 and 3.8, p = 0.016 and p < 0.001), while A+N- patients did not (hazard ratio = 1.13, p = 0.771). In A+N- and A+N+ groups, none of the biomarkers predicted time to progression. In the SNAP group, lower time to progression was correlated with greater hypometabolism (r = 0.42, p = 0.073). Our findings support the notion that patients with SNAP MCI feature a specific risk progression profile..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Neurology - 84(2015), 5, Seite 508-515 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caroli, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Databases, Factual - trends |
| RVK: |
|---|
| doi: |
10.1212/WNL.0000000000001209 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC196245942X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC196245942X | ||
| 003 | DE-627 | ||
| 005 | 20230511081711.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0000000000001209 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC196245942X | ||
| 035 | |a (DE-599)GBVOLC196245942X | ||
| 035 | |a (PRQ)c1946-ffd644e8e7dcb47598241e0649f353e4e49fe6c3fe11b87ab4a21f2445a6fe6f0 | ||
| 035 | |a (KEY)0070612420150000084000500508mildcognitiveimpairmentwithsuspectednonamyloidpath | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Caroli, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The aim of this study was to investigate predictors of progressive cognitive deterioration in patients with suspected non-Alzheimer disease pathology (SNAP) and mild cognitive impairment (MCI). We measured markers of amyloid pathology (CSF β-amyloid 42) and neurodegeneration (hippocampal volume on MRI and cortical metabolism on [(18)F]-fluorodeoxyglucose-PET) in 201 patients with MCI clinically followed for up to 6 years to detect progressive cognitive deterioration. We categorized patients with MCI as A+/A- and N+/N- based on presence/absence of amyloid pathology and neurodegeneration. SNAPs were A-N+ cases. The proportion of progressors was 11% (8/41), 34% (14/41), 56% (19/34), and 71% (60/85) in A-N-, A+N-, SNAP, and A+N+, respectively; the proportion of APOE ε4 carriers was 29%, 70%, 31%, and 71%, respectively, with the SNAP group featuring a significantly different proportion than both A+N- and A+N+ groups (p ≤ 0.005). Hypometabolism in SNAP patients was comparable to A+N+ patients (p = 0.154), while hippocampal atrophy was more severe in SNAP patients (p = 0.002). Compared with A-N-, SNAP and A+N+ patients had significant risk of progressive cognitive deterioration (hazard ratio = 2.7 and 3.8, p = 0.016 and p < 0.001), while A+N- patients did not (hazard ratio = 1.13, p = 0.771). In A+N- and A+N+ groups, none of the biomarkers predicted time to progression. In the SNAP group, lower time to progression was correlated with greater hypometabolism (r = 0.42, p = 0.073). Our findings support the notion that patients with SNAP MCI feature a specific risk progression profile. | ||
| 540 | |a Nutzungsrecht: © 2015 American Academy of Neurology. | ||
| 650 | 4 | |a Databases, Factual - trends | |
| 650 | 4 | |a Neurodegenerative Diseases - diagnosis | |
| 650 | 4 | |a Mild Cognitive Impairment - psychology | |
| 650 | 4 | |a Neurodegenerative Diseases - psychology | |
| 650 | 4 | |a Mild Cognitive Impairment - diagnosis | |
| 700 | 1 | |a Prestia, Annapaola |4 oth | |
| 700 | 1 | |a Galluzzi, Samantha |4 oth | |
| 700 | 1 | |a Ferrari, Clarissa |4 oth | |
| 700 | 1 | |a van der Flier, Wiesje M |4 oth | |
| 700 | 1 | |a Ossenkoppele, Rik |4 oth | |
| 700 | 1 | |a Van Berckel, Bart |4 oth | |
| 700 | 1 | |a Barkhof, Frederik |4 oth | |
| 700 | 1 | |a Teunissen, Charlotte |4 oth | |
| 700 | 1 | |a Wall, Anders E |4 oth | |
| 700 | 1 | |a Carter, Stephen F |4 oth | |
| 700 | 1 | |a Schöll, Michael |4 oth | |
| 700 | 1 | |a Choo, Il Han |4 oth | |
| 700 | 1 | |a Grimmer, Timo |4 oth | |
| 700 | 1 | |a Redolfi, Alberto |4 oth | |
| 700 | 1 | |a Nordberg, Agneta |4 oth | |
| 700 | 1 | |a Scheltens, Philip |4 oth | |
| 700 | 1 | |a Drzezga, Alexander |4 oth | |
| 700 | 1 | |a Frisoni, Giovanni B |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1951 |g 84(2015), 5, Seite 508-515 |w (DE-627)129495174 |w (DE-600)207147-2 |w (DE-576)014893118 |x 0028-3878 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2015 |g number:5 |g pages:508-515 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1212/WNL.0000000000001209 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25568301 |
| 856 | 4 | 2 | |u http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-248195 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_55 | ||
| 912 | |a GBV_ILN_2002 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2410 | ||
| 912 | |a GBV_ILN_2412 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.90 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 84 |j 2015 |e 5 |h 508-515 | ||